Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 197 Published: March 31, 2022 Report Code: GMDGDHC22074IDB

The acute respiratory distress syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

Key Targets in the Acute Respiratory Distress Syndrome Pipeline Market

The key targets in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6, Angiopoietin 1 Receptor, Dipeptidase 1, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, 2019 Novel corona Virus Spike Glycoprotein, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase. ADP Ribosylation Factor 6 has the highest number of pipeline products.

Acute Respiratory Distress Syndrome Pipeline Market, by Targets

Acute Respiratory Distress Syndrome Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Acute Respiratory Distress Syndrome Pipeline Market

The key MoA in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6 Inhibitor, Dipeptidase 1 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, and Alpha 1 Antitrypsin Replacement. ADP Ribosylation Factor 6 Inhibitor has the highest number of pipeline products.

Acute Respiratory Distress Syndrome Pipeline Market, by MoA

Acute Respiratory Distress Syndrome Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Acute Respiratory Distress Syndrome Pipeline Market

The key RoA in the acute respiratory distress syndrome pipeline market are intravenous, oral, inhalational, parenteral, subcutaneous, intraarticular, and intraperitoneal. Intravenous has the highest number of pipeline products.

Acute Respiratory Distress Syndrome Pipeline Market, by RoA

Acute Respiratory Distress Syndrome Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Acute Respiratory Distress Syndrome Pipeline Market

The key molecule type in the acute respiratory distress syndrome pipeline market are small molecule, cell therapy, biologic, peptide, gene-modified cell therapy, monoclonal antibody, synthetic peptide, oligonucleotide, and recombinant protein. Small molecule has the highest number of pipeline products in the acute respiratory distress syndrome pipeline market.

Acute Respiratory Distress Syndrome Pipeline Market, by Molecule Type

Acute Respiratory Distress Syndrome Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the Acute Respiratory Distress Syndrome Pipeline Market

The key companies in the acute respiratory distress syndrome pipeline market are Bayer AG, BioStem Technologies Inc, Pantherna Therapeutics GmbH, A6 Pharmaceuticals LLC, Arch Biopartners Inc, Athersys Inc, Faron Pharmaceuticals Oy, and Meridigen Biotech Co Ltdz. Bayer AG has the highest number of pipeline products.

Acute Respiratory Distress Syndrome Pipeline Market, by Companies

Acute Respiratory Distress Syndrome Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets ADP Ribosylation Factor 6, Angiopoietin 1 Receptor, Dipeptidase 1, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, 2019 Novel corona Virus Spike Glycoprotein, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase
Key MoA ADP Ribosylation Factor 6 Inhibitor, Dipeptidase 1 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, and Alpha 1 Antitrypsin Replacement
Key RoA Intravenous, Oral, Inhalational, Parenteral, Subcutaneous, Intraarticular, and Intraperitoneal
Key molecule type Small Molecule, Cell Therapy, Biologic, Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody, Synthetic Peptide, Oligonucleotide, and Recombinant Protein
Key companies Bayer AG, BioStem Technologies Inc, Pantherna Therapeutics GmbH, A6 Pharmaceuticals LLC, Arch Biopartners Inc, Athersys Inc, Faron Pharmaceuticals Oy, and Meridigen Biotech Co Ltdz

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

A6 Pharmaceuticals LLC

Abbreos Inc

AcelRx Pharmaceuticals Inc

Akttyva Therapeutics Inc

Alveolus Bio Inc

AMNICELL Corp Ltd

Ampio Pharmaceuticals Inc

APEIRON Biologics AG

ARBORMED Pharmaceuticals Inc

Arch Biopartners Inc

Athersys Inc

Avalon GloboCare Corp

Aviceda Therapeutics

AVM Biotechnology LLC

Bayer AG

Biocon Ltd

BioMarck Pharmaceuticals Ltd

BioStem Technologies Inc

Bioxytran Inc

Bonus BioGroup Ltd

Cartesian Therapeutics Inc

Cellular Biomedicine Group Ltd

Cellvation Inc

Celularity Inc

Curacle Co Ltd

Cytonus Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Dianomi Therapeutics Inc

Emergent BioSolutions Inc

Endece LLC

Enlivex Therapeutics Ltd

Eunoia Biotech LLC

Exvastat Ltd

Faron Pharmaceuticals Oy

GentiBio Inc

Green Cross LabCell Corp

Grifols SA

Haisco Pharmaceutical Group Co Ltd

Histocell SL

ImmunityBio Inc

Implicit Bioscience Ltd

Imstem Biotechnology Inc

In2cure AB

IsletOne AB

Kalvista Pharmaceuticals Inc

Kubota Vision Inc

Kyorin Pharmaceutical Co Ltd

Liminal BioSciences Inc

LTT Bio-Pharma Co Ltd

MannKind Corp

MDI Therapeutics Inc

MediPost Co Ltd

Medsenic SAS

Meridigen Biotech Co Ltd

Nano Biotherapeutics Inc

Neutrolis Inc

Northern Therapeutics Inc

NS Pharma Inc

Nuvara Therapeutics LLC

OGB1 Inc

Omnispirant Ltd

Orion Biotechnology Canada Ltd

Pantherna Therapeutics GmbH

PharmAbcine Inc

Restore Therapeutics LLC

RION Health Inc

Shanghai Henlius Biotech Inc

SolAeroMed Inc

Sorrento Therapeutics Inc

Systimmune Inc

Thetis Pharmaceuticals LLC

Vasomune Inc

Veru Inc

Windtree Therapeutics Inc

Xfibra Inc

Xintela AB

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome – Overview

Acute Respiratory Distress Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome – Companies Involved in Therapeutics Development

A6 Pharmaceuticals LLC

Abbreos Inc

AcelRx Pharmaceuticals Inc

Akttyva Therapeutics Inc

Alveolus Bio Inc

AMNICELL Corp Ltd

Ampio Pharmaceuticals Inc

APEIRON Biologics AG

ARBORMED Pharmaceuticals Inc

Arch Biopartners Inc

Athersys Inc

Avalon GloboCare Corp

Aviceda Therapeutics

AVM Biotechnology LLC

Bayer AG

Biocon Ltd

BioMarck Pharmaceuticals Ltd

BioStem Technologies Inc

Bioxytran Inc

Bonus BioGroup Ltd

Cartesian Therapeutics Inc

Cellular Biomedicine Group Ltd

Cellvation Inc

Celularity Inc

Curacle Co Ltd

Cytonus Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Dianomi Therapeutics Inc

Emergent BioSolutions Inc

Endece LLC

Enlivex Therapeutics Ltd

Eunoia Biotech LLC

Exvastat Ltd

Faron Pharmaceuticals Oy

GentiBio Inc

Green Cross LabCell Corp

Grifols SA

Haisco Pharmaceutical Group Co Ltd

Histocell SL

ImmunityBio Inc

Implicit Bioscience Ltd

Imstem Biotechnology Inc

In2cure AB

IsletOne AB

Kalvista Pharmaceuticals Inc

Kubota Vision Inc

Kyorin Pharmaceutical Co Ltd

Liminal BioSciences Inc

LTT Bio-Pharma Co Ltd

MannKind Corp

MDI Therapeutics Inc

MediPost Co Ltd

Medsenic SAS

Meridigen Biotech Co Ltd

Nano Biotherapeutics Inc

Neutrolis Inc

Northern Therapeutics Inc

NS Pharma Inc

Nuvara Therapeutics LLC

OGB1 Inc

Omnispirant Ltd

Orion Biotechnology Canada Ltd

Pantherna Therapeutics GmbH

PharmAbcine Inc

Restore Therapeutics LLC

RION Health Inc

Shanghai Henlius Biotech Inc

SolAeroMed Inc

Sorrento Therapeutics Inc

Systimmune Inc

Thetis Pharmaceuticals LLC

Vasomune Inc

Veru Inc

Windtree Therapeutics Inc

Xfibra Inc

Xintela AB

ZyVersa Therapeutics Inc

Acute Respiratory Distress Syndrome – Drug Profiles

(cannabidiol + hydroxychloroquine) – Drug Profile

Product Description

Mechanism Of Action

History of Events

A6-5188 – Drug Profile

Product Description

Mechanism Of Action

AB-5000 – Drug Profile

Product Description

Mechanism Of Action

ABB-201 – Drug Profile

Product Description

Mechanism Of Action

abivertinib maleate – Drug Profile

Product Description

Mechanism Of Action

History of Events

AKT-001 – Drug Profile

Product Description

Mechanism Of Action

alpha-1 proteinase inhibitor (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Ampion – Drug Profile

Product Description

Mechanism Of Action

History of Events

APN-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ApoCell – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARBM-201 – Drug Profile

Product Description

Mechanism Of Action

AV-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVD-1010 – Drug Profile

Product Description

Mechanism Of Action

BAY-1097761 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BAY-1211163 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BDTp-231 – Drug Profile

Product Description

Mechanism Of Action

BIO-11006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory – Drug Profile

Product Description

Mechanism Of Action

Biologics for Acute Respiratory Distress Syndrome and Sepsis – Drug Profile

Product Description

Mechanism Of Action

BSEM-001 – Drug Profile

Product Description

Mechanism Of Action

BSEM-002 – Drug Profile

Product Description

Mechanism Of Action

BSEM-003 – Drug Profile

Product Description

Mechanism Of Action

BXT-25 – Drug Profile

Product Description

Mechanism Of Action

CBMSC-1 – Drug Profile

Product Description

Mechanism Of Action

CEVA-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CT-303 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CU-06 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CYNK-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Descartes-30 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dexamethasone sodium phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs for Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

DTX-020 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DWP-710 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

HCR-040 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HLX-70 – Drug Profile

Product Description

Mechanism Of Action

HSK-31858 – Drug Profile

Product Description

Mechanism Of Action

ibudilast – Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-14 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-200 – Drug Profile

Product Description

Mechanism Of Action

ilginatinib – Drug Profile

Product Description

Mechanism Of Action

imatinib mesylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

IMS-001 – Drug Profile

Product Description

Mechanism Of Action

interferon beta-1a – Drug Profile

Product Description

Mechanism Of Action

History of Events

invimestrocel – Drug Profile

Product Description

Mechanism Of Action

History of Events

IO-2 – Drug Profile

Product Description

Mechanism Of Action

itolizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

KV-998052 – Drug Profile

Product Description

Mechanism Of Action

LT-1001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LTX-608 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MCS-222 – Drug Profile

Product Description

Mechanism Of Action

MDI-2517 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MesenCure – Drug Profile

Product Description

Mechanism Of Action

History of Events

Metablok – Drug Profile

Product Description

Mechanism Of Action

History of Events

NAV-5093 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NDC-1308 – Drug Profile

Product Description

Mechanism Of Action

NTR-452 – Drug Profile

Product Description

Mechanism Of Action

OB-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OS-002 – Drug Profile

Product Description

Mechanism Of Action

PAN-004 – Drug Profile

Product Description

Mechanism Of Action

PAN-006 – Drug Profile

Product Description

Mechanism Of Action

PAN-007 – Drug Profile

Product Description

Mechanism Of Action

Peptide for Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

piceatannol albumin bound – Drug Profile

Product Description

Mechanism Of Action

History of Events

plasminogen (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

PMC-402 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Polymer for Acute Lung Injury and Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

PXVX-0047 – Drug Profile

Product Description

Mechanism Of Action

History of Events

REGEND-007 – Drug Profile

Product Description

Mechanism Of Action

REGEND-008 – Drug Profile

Product Description

Mechanism Of Action

S-1229 – Drug Profile

Product Description

Mechanism Of Action

History of Events

sabizabulin – Drug Profile

Product Description

Mechanism Of Action

History of Events

SIF-019 – Drug Profile

Product Description

Mechanism Of Action

History of Events

simvastatin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit VAP-1 for Ophthalmology and Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

SMUPIV-01 – Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy for Infectious Diseases and Respiratory Disorders – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides for Acute Lung Injury and Acute Respiratory Distress Syndrome – Drug Profile

Product Description

Mechanism Of Action

TCP-25 – Drug Profile

Product Description

Mechanism Of Action

TP-317 – Drug Profile

Product Description

Mechanism Of Action

History of Events

UMC-11906 – Drug Profile

Product Description

Mechanism Of Action

UMC-11912 – Drug Profile

Product Description

Mechanism Of Action

Viral Acute Respiratory Distress Syndrome (V-ARDS) – Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-025 – Drug Profile

Product Description

Mechanism Of Action

XFB-19 – Drug Profile

Product Description

Mechanism Of Action

History of Events

XSTEM – Drug Profile

Product Description

Mechanism Of Action

History of Events

Acute Respiratory Distress Syndrome – Dormant Projects

Acute Respiratory Distress Syndrome – Discontinued Products

Acute Respiratory Distress Syndrome – Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: Healios plans preapplication consultation with PMDA on MultiStem as early as March

Feb 03, 2022: Faron Pharmaceuticals : Scientific reports publishes INFORAAA results showing traumakine-induced up-regulation of CD73 prevents death after emergency open aortic surgery

Jan 26, 2022: Athersys to host a virtual presentation on its MultiStem programs

Nov 30, 2021: Report of placebo-controlled clinical trial evaluating Multistem cell therapy for acute respiratory distress syndrome published in intensive care medicine

Nov 12, 2021: Athersys reports updates on timing for Japan ARDS and stroke programs from Healios K.K.

Sep 28, 2021: Athersys to present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference

Aug 09, 2021: Healios reports positive data of cell therapy in ARDS patients

Jul 21, 2021: Enlivex to present at the Improvate Life-Saving Technologies International Conference 2021

Jul 14, 2021: Enlivex to present at the ARDS Drug Development Summit 2021

Jul 07, 2021: Results of Biomarck clinical and preclinical studies of BIO-11006 in ARDS to be presented at the 2021 ARDS Drug Development Summit

Jun 30, 2021: New publication provides further clarity of multistem’s mechanism of action on modulating the inflammatory response in critical care indications

Jun 28, 2021: MediciNova to conduct mouse study under partnership with BARDA to develop MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury

May 12, 2021: Results of Biomarck phase II study of BIO-11006 in patients with ARDS to be presented at the 2021 ATS Annual Meeting

Apr 06, 2021: Xintela reports positive results from preclinical ARDS study and new grant of

2.3 million SEK

Mar 31, 2021: Athersys reports that healios has completed enrollment in the ONE-BRIDGE study of MultiStem for Acute Respiratory Distress Syndrome in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Acute Respiratory Distress Syndrome – Pipeline by A6 Pharmaceuticals LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by Abbreos Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by AcelRx Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Akttyva Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Alveolus Bio Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by AMNICELL Corp Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Ampio Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by APEIRON Biologics AG, 2022

Acute Respiratory Distress Syndrome – Pipeline by ARBORMED Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Arch Biopartners Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Athersys Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Avalon GloboCare Corp, 2022

Acute Respiratory Distress Syndrome – Pipeline by Aviceda Therapeutics, 2022

Acute Respiratory Distress Syndrome – Pipeline by AVM Biotechnology LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by Bayer AG, 2022

Acute Respiratory Distress Syndrome – Pipeline by Biocon Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by BioMarck Pharmaceuticals Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by BioStem Technologies Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Bioxytran Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Bonus BioGroup Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Cartesian Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Cellular Biomedicine Group Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Cellvation Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Celularity Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Curacle Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Cytonus Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Dianomi Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Emergent BioSolutions Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Endece LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by Enlivex Therapeutics Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Eunoia Biotech LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by Exvastat Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Faron Pharmaceuticals Oy, 2022

Acute Respiratory Distress Syndrome – Pipeline by GentiBio Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Green Cross LabCell Corp, 2022

Acute Respiratory Distress Syndrome – Pipeline by Grifols SA, 2022

Acute Respiratory Distress Syndrome – Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Histocell SL, 2022

Acute Respiratory Distress Syndrome – Pipeline by ImmunityBio Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Implicit Bioscience Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Imstem Biotechnology Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by In2cure AB, 2022

Acute Respiratory Distress Syndrome – Pipeline by IsletOne AB, 2022

Acute Respiratory Distress Syndrome – Pipeline by Kalvista Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Kubota Vision Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Kyorin Pharmaceutical Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Liminal BioSciences Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by LTT Bio-Pharma Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by MannKind Corp, 2022

Acute Respiratory Distress Syndrome – Pipeline by MDI Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by MediPost Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Medsenic SAS, 2022

Acute Respiratory Distress Syndrome – Pipeline by Meridigen Biotech Co Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Nano Biotherapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Neutrolis Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Northern Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by NS Pharma Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Nuvara Therapeutics LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by OGB1 Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Omnispirant Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Orion Biotechnology Canada Ltd, 2022

Acute Respiratory Distress Syndrome – Pipeline by Pantherna Therapeutics GmbH, 2022

Acute Respiratory Distress Syndrome – Pipeline by PharmAbcine Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Restore Therapeutics LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by RION Health Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Shanghai Henlius Biotech Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by SolAeroMed Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Sorrento Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Systimmune Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Thetis Pharmaceuticals LLC, 2022

Acute Respiratory Distress Syndrome – Pipeline by Vasomune Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Veru Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Windtree Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Xfibra Inc, 2022

Acute Respiratory Distress Syndrome – Pipeline by Xintela AB, 2022

Acute Respiratory Distress Syndrome – Pipeline by ZyVersa Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome – Dormant Projects, 2022

Acute Respiratory Distress Syndrome – Dormant Projects, 2022 (Contd..1)

Acute Respiratory Distress Syndrome – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.